TABLE 1.
Baseline characteristics of OPEN study participants by allocated treatment1
Vitamin B-12 | Placebo | |
Participants, n | 99 | 102 |
Sex, M, n (%) | 46 (46.5) | 48 (47.1) |
Age | ||
Age, y | 79.9 ± 3.52 | 80.1 ± 3.7 |
75–79, n (%) | 56 (56.6) | 57 (55.9) |
≥80, n (%) | 43 (43.4) | 45 (44.1) |
Education | ||
Age at leaving, y | 18.3 ± 5.3 | 17.8 ± 6.6 |
No qualifications, n (%) | 21 (21.4) | 33 (33.0) |
Basic or clerical, n (%) | 16 (16.3) | 18 (18.0) |
Advanced or university, n (%) | 33 (33.7) | 19 (19.0) |
Other, n (%) | 28 (28.6) | 30 (30.0) |
Vascular health | ||
Myocardial infarction in 5 y, n (%) | 1 (1.0) | 4 (3.9) |
Stroke in 5 y, n (%) | 1 (1.0) | 0 |
BMI, kg/m2 | 27.0 ± 5.6 | 27.5 ± 5.3 |
<18.5, n (%) | 1 (1.0) | 0 |
≥30, n (%) | 18 (18.2) | 25 (24.8) |
Mini-Mental State Examination score | 29 (28–29)3 | 29 (28–29) |
Current prescription drugs,4 n (%) | ||
Statins | 32 (38.1) | 35 (44.9) |
Proton-pump inhibitors | 26 (31.0) | 27 (34.6) |
Other relevant | 1 (1.2) | 2 (2.6) |
Dietary pattern, n (%) | ||
>1 portion meat/wk | 69 (73.4) | 70 (72.2) |
>1 portion oily fish/wk | 16 (18.0) | 22 (23.4) |
>1 portion white fish/wk | 21 (21.9) | 18 (18.8) |
>1 portion eggs/wk | 47 (48.5) | 38 (39.2) |
Daily alcohol | 33 (34.4) | 35 (35.4) |
Blood biochemical measure | ||
Participants, n | 86 | 84 |
Vitamin B-12, pmol/L | 222.9 (197.4–268.9) | 228.0 (194.7–271.0) |
Holotranscobalamin, pmol/L | 50.4 (38.2–68.3) | 48.8 (39.8–62.9) |
Homocysteine, μmol/L | 15.9 (14.0–18.9) | 16.3 (13.3–19.9) |
Folate, nmol/L | 17.7 (10.8–25.4) | 17.5 (11.8–25.4) |
Hemoglobin, g/L | 139.8 ± 11.1 | 138.9 ± 12.9 |
OPEN, Older People and Enhanced Neurological Function.
Mean ± SD (all such values).
Median; IQR in parentheses (all such values).
Drug categories were as follows: statins (simvastatin, atorvastatin, pravastatin, and rosuvastatin); proton-pump inhibitors (omeprazole, lansoprazole, esomeprazole, rabeprazole, and pantoprazole); and other relevant drugs (amiodarone and metronidazole).